ArticleTheranostics2020
Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- A Preliminary Evaluation ofPharmaceutics · 2026Article
- Radiochemistry and comparative in vitro assessment of PSMA-617 labeled with lead-212 (EJNMMI radiopharmacy and chemistry · 2026Article
- Editorial: Radiolabeled Peptides in Cancer Imaging and Therapy-Emerging Isotopes.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Therapeutic evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Prostate-Specific Membrane Antigen (PSMA)-Directed Dendrimer-Camptothecin Conjugate for Targeted Treatment of Prostate Cancer.ACS applied nano materials · 2025Article
- Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Evaluating [European journal of nuclear medicine and molecular imaging · 2024Article
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board.EJNMMI radiopharmacy and chemistry · 2024Review
- Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.International journal of molecular sciences · 2024Article
- Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics · 2024Review
- Tandem Isotope Therapy withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- [Cancers · 2022Article
- Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225.EJNMMI research · 2022Article
- In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.European journal of nuclear medicine and molecular imaging · 2022Article
- A novel mouse model for liver metastasis of prostate cancer reveals dynamic tumour-immune cell communication.Cell proliferation · 2021Article
- Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancers · 2021Review
- Evaluation of Actinium-225 Labeled Minigastrin Analogue [Pharmaceutics · 2020Article
- Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.Cancer biotherapy & radiopharmaceuticals · 2020Article
- Actinium-225 in Targeted Alpha Therapy.Journal of medical physicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Andreea D StuparuAhmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA, USA.
Catherine A L MeyerAhmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA, USA.
Susan L Evans-AxelssonDepartment of Translational Medicine, Division of Urological Cancers, Skåne University Hospital Malmö, Lund University, Sweden.
Katharina LückerathAhmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA, USA.
Liu H WeiAhmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA, USA.
Woosuk KimAhmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA, USA.
Soumya PoddarAhmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA, USA.
Christine E MonaAhmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA, USA.
Magnus DahlbomAhmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA, USA.
Mark D GirgisDepartment of Surgery, David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA, USA.
Caius G RaduAhmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA, USA.
Johannes CzerninAhmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA, USA.
Roger SlavikAhmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA, USA.
Skåne University Hospital · SE
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MUCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2MNCI NIH HHS P30 CA016042NCI NIH HHS P50 CA092131NCI NIH HHS P50 CA211015
Abstract
PubMed holds no abstract for this paper.
Indexed as
ActiniumAlpha ParticlesAnimalsCell Line, TumorDipeptidesDisease Models, AnimalFeasibility StudiesHeterocyclic Compounds, 1-RingHumansMaleMiceProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantRadiopharmaceuticalsActiniumActinium-225DipeptidesHeterocyclic Compounds, 1-RingProstate-Specific AntigenPSMA-617Radiopharmaceuticalsactiniummetastatic mouse modelprostate cancerPSMAtargeted alpha therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.